# Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

> **NCT04486833** · PHASE1,PHASE2 · RECRUITING · sponsor: **Genprex, Inc.** · enrollment: 158 (estimated)

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **BIOLOGICAL:** quaratusugene ozeplasmid
- **DRUG:** osimertinib
- **DRUG:** Platinum-Based Chemotherapy

## Key facts

- **NCT ID:** NCT04486833
- **Lead sponsor:** Genprex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-03
- **Primary completion:** 2028-03
- **Final completion:** 2029-03
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486833, "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04486833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*